Important Information for TransMedics Group, Inc. Securities Holders: Rosen Law Firm Announces Securities Class Action and Lead Plaintiff Deadline
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023, and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025, lead plaintiff deadline in the securities class action first filed by the Firm. This announcement comes after TransMedics announced its fourth-quarter and full-year 2024 financial results, which revealed disappointing revenue growth and increased operating expenses.
What Happened to TransMedics Group, Inc.?
TransMedics is a medical technology company that specializes in organ preservation and transplantation solutions. The Company’s flagship product, the Organ Care System (OCS), is designed to maintain the functionality of donated organs outside the body until they can be transplanted. However, during the Class Period, TransMedics failed to disclose material information regarding the commercialization of its OCS, leading to artificially inflated stock prices.
How This Affects TransMedics Securities Holders
If you purchased TransMedics securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that TransMedics and certain of its executives made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects. These false statements and omissions artificially inflated the price of TransMedics securities, causing investors harm.
How This Affects the World
The securities class action against TransMedics could have significant implications for the medical technology industry and investor confidence. TransMedics’ failure to disclose material information regarding the commercialization of its OCS could deter investors from trusting other medical technology companies, potentially hindering their ability to raise capital and grow. Additionally, the lawsuit could lead to increased scrutiny and regulation of the medical technology industry as a whole.
Conclusion
If you purchased TransMedics securities between February 28, 2023, and January 10, 2025, and believe that you have suffered a loss as a result of the Company’s false and/or misleading statements, you may be entitled to compensation. Contact Rosen Law Firm before the lead plaintiff deadline of April 15, 2025, to discuss your potential claim. The Firm welcomes you to join a class action that seeks to hold TransMedics and its executives responsible for their actions. Together, we can work towards securing justice and accountability for all affected investors.
- TransMedics Group, Inc. (NASDAQ: TMDX)
- Fourth-quarter and full-year 2024 financial results
- Disappointing revenue growth and increased operating expenses
- Class Period: February 28, 2023, to January 10, 2025
- Lead Plaintiff Deadline: April 15, 2025
- Securities Class Action
- Allegations of false and/or misleading statements and omissions
- Potential compensation for affected investors
